OSMOVIST 240 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Osmovist 240, and what generic alternatives are available?
Osmovist 240 is a drug marketed by Bayer Hlthcare and is included in one NDA.
The generic ingredient in OSMOVIST 240 is iotrolan. Additional details are available on the iotrolan profile page.
Summary for OSMOVIST 240
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 38 |
Patent Applications: | 1,110 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OSMOVIST 240 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for OSMOVIST 240
US Patents and Regulatory Information for OSMOVIST 240
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Hlthcare | OSMOVIST 240 | iotrolan | INJECTABLE;INTRATHECAL | 019580-002 | Dec 7, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |